Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Leuk Lymphoma. 2014 Apr 29;55(12):2822–2829. doi: 10.3109/10428194.2014.901513

Table 2. Survival data.

Variable Univariate Multivariate
HR (95%CI) p HR (95%CI) p
NCCN prognostic group: 2.72 (2.00-3.78) <0.001 1.92 (1.40-2.69) <0.001
 •intermediate/good 2.01 (1.71-2.35) <0.001 2.01 (1.71-2.37) <0.001
 •poor/intermediate
Age>60 2.13 (1.83-2.48) <0.001 1.53 (1.30-1.81) <0.001
PS>1 1.80 (1.49-2.16) <0.001 1.56 (1.28-1.89) <0.001
CD34>median 1.23 (1.06-1.42) 0.005 1.07 (0.91-1.25) 0.379
Male gender 1.02 (0.88-1.18) 0.779 1.00 (0.86-1.17) 0.952
Year of Diagnosis 1.13 (0.96-1.33) 0.12 1.08 (0.91-1.28) 0.359
 •2000-2003/2004-2008 1.34 (1.09-1.66) <0.001 1.22 (0.97-1.53) 0.07
 •2004-2008/2009-2012
Response to treatment 7.47 (5.22-10.44) <0.001 6.97 (4.69-10.06) <0.001
 •Died/poor 3.17 (2.7-3.72) <0.001 2.35 (1.97-2.80) <0.001
 •Poor/complete
CCBs 1.6 (1.22-2.06) <0.001 1.39(1.05-1.80) 0.02